Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published February 2021 | Supplemental Material + Accepted Version
Journal Article Open

MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF^(V600E)-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance

Abstract

Micro-RNAs are important post-transcriptional regulators of cell fate both in normal and disease states. miR-211 has previously been shown to be a direct regulator of metabolism in BRAF^(V600E)-mutant melanoma cells in vitro. Here we report that miR-211 expression promotes aggressive growth of BRAF^(V600E)-mutant melanoma xenografts in vivo. miR-211 promoted proliferation through post-transcriptional activation of ERK5 signaling, which has recently been implicated in BRAF and MEK inhibitor resistance. We therefore examined whether miR-211 similarly modulated melanoma resistance to the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. Consistent with this model, miR-211 expression increased melanoma cell resistance to both inhibitors and this resistance was associated with increased ERK5 phosphorylation. miR-211 mediates these effects by directly inhibiting the expression of DUSP6, an ERK5 pathway-specific phosphatase and now shown to be an miR-211 target gene. These results dissect the role of the miR-211-DUSP6-ERK5 axis in melanoma tumor growth and suggest a mechanism for the development of drug-resistant tumors and a target for overcoming resistance.

Additional Information

© 2020 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. Received 27 September 2019, Revised 17 June 2020, Accepted 22 June 2020, Available online 2 September 2020. We thank Jeffrey M. Trent (Translational Genomics Institute, Phoenix, AZ), who originally provided the 33 UACC cell lines, and Neal Rosen (Memorial Sloan Kettering Cancer Center, New York, NY), who provided the five SK-MEL and MeWo cell lines. This work was supported by National Institutes of Health grants (R21CA202197, CA165184, National Cancer Institute 5P30CA030199 [SBP], P30 CA006973 [Johns Hopkins University-Sidney Kimmel Comprehensive Cancer Center) and Florida Department of Health, Bankhead-Coley Cancer Research Program (5BC08) to RJP. Author Contributions: Conceptualization: RJP, AR, BL; Data Curation: BL; Formal Analysis: BL, PRDJ; Funding Acquisition: RJP; Investigation: BL, AS, JS, JM, SS, FIALL, DF, JM, PJ, MK, PRDJ; Methodology: BL; Project Administration: RJP; Resources: KV; Supervision: RJP; Validation: BL, AS, SS, RJP; Visualization: BL, PJ, RJP; Writing - Original Draft Preparation: BL, RJP; Writing - Review and Editing: RJP, BL, AR. The authors state no conflicts of interest. Data availability statement: All xenografts RNA-seq and argonaute-2 RNA immunopurification and sequencing datasets have been deposited in the Gene Expression Omnibus under accession number GSE125836.

Attached Files

Accepted Version - nihms-1626963.pdf

Supplemental Material - 1-s2.0-S0022202X20320431-mmc1.pdf

Files

1-s2.0-S0022202X20320431-mmc1.pdf
Files (3.7 MB)
Name Size Download all
md5:11457f475087fb3359a9c2e4495555a2
1.8 MB Preview Download
md5:ad51f9fa05e9cf6162439dea3708ca5e
1.9 MB Preview Download

Additional details

Created:
August 20, 2023
Modified:
October 20, 2023